In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crying Wolf?

Executive Summary

Today, drug companies are experiencing unprecedented success on precisely the terms that managed care should have denied it: robust pricing and profitability and a new definition of success for individual products, the mega-blockbuster. Aggressive direct-to-consumer ad campaigns and the success of new, so-called lifestyle or cosmetic drugs, such as {Viagra}, only underscore the impotence of managed care organizations in their efforts to rein-in pharmaceutifal costs. But there are rumblings in some corners of the industry that drug companies take managed care's impotence for granted at their peril.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

IV001054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel